featured
ESMO 2020: Pembrolizumab Plus Chemotherapy Outperforms Chemotherapy Alone in Advanced Esophageal Cancer
Study authors suggest that the combination should be the new standard of care, but expert recommends caution
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.